AGENTS FOR TREATING TUMORS, USE AND METHOD THEREOF

• US 20150344577A1
• Filed: 01/11/2013
• Published: 12/03/2015
• Est. Priority Date: 01/11/2013
• Status: Abandoned Application

• Current Assignee: Dingfu Biotarget Co., Ltd.
• Original Assignee: Dingfu Biotarget Co., Ltd.
• Inventors: FU, Yangxin
• Application Number:
  US14/654,648
• Publication Number:
  US 20150344577A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 5/10 X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy A61N5/01 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/2818 against CD28 or CD152
• CPC Class Codes: C07K 16/2827 against B7 molecules, e.g. CD80, CD86
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present disclosure provides agents for treating and/or preventing resistance of tumor cells to radiation therapy (RT), the use and relevant method thereof.

Claims

1. A method of reducing resistance of a tumor to radiation therapy comprising administering to a subject in need thereof an agent inhibiting B7-H1/PD1 signaling.

2. The method of claim 1, wherein said agent inhibiting B7-H1/PD1 signaling is an inhibitor of B7-H1 or PD1 activity.

3. The method of claim 1, wherein the agent inhibiting B7-H1/PD1 signaling is an inhibitor of B7-H1 activity.

4. The method of claim 1, wherein the radiation therapy is one or more X-ray irradiations.

5. The method of claim 1, wherein the tumor is breast cancer, ovarian cancer, bladder cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer or melanoma and/or cells thereof.

6. The method of claim 1, further comprising administering to the subject a chemotherapeutic agent.

7. The method of claim 2, wherein the inhibitor of B7-H1 or PD1 activity is a blocking antibody to B7-H1 or PD1.

8. The method of claim 3, wherein the inhibitor of B7-H1 activity is a blocking antibody to B7-H1.

9. The method of claim 8, wherein the blocking antibody to B7-H1 is a monoclonal antibody.

10. The method of claim 4, wherein the one or more X-ray irradiations is one to six X-ray irradiations.

11. The method of claim 4, wherein each of the one or more X-ray irradiations comprises an X-ray dosage of 5-20 Gy.

12. The method of claim 11, wherein the X-ray dosage is 5-8 Gy.

13. The method of claim 11, wherein the X-ray dosage is 5-12 Gy.

14. The method of claim 11, wherein the X-ray dosage is 5-15 Gy.

15. The method of claim 5, wherein the tumor comprises breast cancer cells.

16. The method of claim 15, wherein the breast cancer cells are TUBO cells.

17. The method of claim 5, wherein the tumor comprises prostate cancer cells.

18. The method of claim 17, wherein the prostate cancer cells are Myc-Cap prostate cancer cells.